Showing results (381-390 of 432) with videos related to

Sort By:
Pageof 44
Plos One|November 3, 2012
Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancerValeria Stuardo, Cristina Agustí, José Manuel Godinez, et al.
Diagnostic Microbiology and Infectious Disease|May 9, 2006
Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimensMíriam J Alvarez-Martínez, José M Miró, Maria Eugenia Valls, et al.
HIV Medicine|December 9, 2021
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in EuropeSarah Amele, Anastasia Karachalia Sandri, Alison Rodger, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|May 24, 2017
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsAntonio Rivero, José Antonio Pérez-Molina, Antonio Javier Blasco, et al.
Frontiers in Immunology|May 6, 2022
Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV ControlJenifer Masip, Norma Rallón, Elena Yeregui, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Infectious Diseases and Therapy|April 11, 2022
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
AIDS Research and Therapy|August 6, 2022
Observational cohort study of rilpivirine (RPV) utilization in EuropeAlessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, et al.
The Journal of Infectious Diseases|October 13, 2018
Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite ControlEsther Rodríguez-Gallego, Laura Tarancón-Diez, Felipe García, et al.
Pageof 44